Department of Genetics and Genomic Sciences and Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, New York.
Sema4, Stamford, Connecticut.
J Clin Endocrinol Metab. 2021 Mar 8;106(3):826-842. doi: 10.1210/clinem/dgaa853.
Pituitary corticotroph adenomas are rare tumors that can be associated with excess adrenocorticotropin (ACTH) and adrenal cortisol production, resulting in the clinically debilitating endocrine condition Cushing disease. A subset of corticotroph tumors behave aggressively, and genomic drivers behind the development of these tumors are largely unknown.
To investigate genomic drivers of corticotroph tumors at risk for aggressive behavior.
Whole-exome sequencing of patient-matched corticotroph tumor and normal deoxyribonucleic acid (DNA) from a patient cohort enriched for tumors at risk for aggressive behavior.
Tertiary care center.
Twenty-seven corticotroph tumors from 22 patients were analyzed. Twelve tumors were macroadenomas, of which 6 were silent ACTH tumors, 2 were Crooke's cell tumors, and 1 was a corticotroph carcinoma.
Whole-exome sequencing.
Somatic mutation genomic biomarkers.
We found recurrent somatic mutations in USP8 and TP53 genes, both with higher allelic fractions than other somatic mutations. These mutations were mutually exclusive, with TP53 mutations occurring only in USP8 wildtype (WT) tumors, indicating they may be independent driver genes. USP8-WT tumors were characterized by extensive somatic copy number variation compared with USP8-mutated tumors. Independent of molecular driver status, we found an association between invasiveness, macroadenomas, and aneuploidy.
Our data suggest that corticotroph tumors may be categorized into a USP8-mutated, genome-stable subtype versus a USP8-WT, genome-disrupted subtype, the latter of which has a TP53-mutated subtype with high level of chromosome instability. These findings could help identify high risk corticotroph tumors, namely those with widespread CNV, that may need closer monitoring and more aggressive treatment.
垂体促肾上腺皮质激素腺瘤是罕见的肿瘤,可与过量促肾上腺皮质激素(ACTH)和肾上腺皮质醇产生相关,导致临床上使人衰弱的内分泌疾病库欣病。一部分促肾上腺皮质激素肿瘤表现出侵袭性,而这些肿瘤发展背后的基因组驱动因素在很大程度上尚不清楚。
研究具有侵袭性行为风险的促肾上腺皮质激素肿瘤的基因组驱动因素。
对患者队列中具有侵袭性行为风险的促肾上腺皮质激素肿瘤的患者匹配的促肾上腺皮质激素肿瘤和正常脱氧核糖核酸(DNA)进行全外显子组测序。
三级护理中心。
分析了 22 名患者的 27 个促肾上腺皮质激素肿瘤。12 个肿瘤为大腺瘤,其中 6 个为无活性 ACTH 肿瘤,2 个为 Crooke 细胞肿瘤,1 个为促肾上腺皮质激素癌。
全外显子组测序。
体细胞突变基因组生物标志物。
我们发现 USP8 和 TP53 基因的反复出现体细胞突变,其等位基因分数均高于其他体细胞突变。这些突变是相互排斥的,TP53 突变仅发生在 USP8 野生型(WT)肿瘤中,表明它们可能是独立的驱动基因。与 USP8 突变肿瘤相比,USP8-WT 肿瘤具有广泛的体细胞拷贝数变异。独立于分子驱动状态,我们发现侵袭性、大腺瘤和非整倍体之间存在关联。
我们的数据表明,促肾上腺皮质激素肿瘤可能分为 USP8 突变、基因组稳定亚型与 USP8-WT、基因组破坏亚型,后者具有高水平染色体不稳定性的 TP53 突变亚型。这些发现可以帮助识别高危促肾上腺皮质激素肿瘤,即那些具有广泛 CNV 的肿瘤,这些肿瘤可能需要更密切的监测和更积极的治疗。